{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:07:25Z","timestamp":1770901645793,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T00:00:00Z","timestamp":1484611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T00:00:00Z","timestamp":1484611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Von Hippel-Lindau (VHL)-associated hemangioblastomas (VHL-HB) arise in the central nervous system (CNS), and are a leading cause of morbidity and mortality in VHL disease. Currently, surgical resection is the most effective way to manage symptomatic VHL-HBs. Surgically unresectable VHL-HBs or those in frail patients are challenging problems. Therapies targeting oncologic and vascular endothelial growth factor (VEGF) pathways have failed to demonstrate tumor control. Our experience and previous reports on VHL-HB avidity to somatostatin analogues suggested somatostatin receptor (SSTR) expression in VHL-HBs, offering an alternative therapeutic strategy. We explored this possibility by demonstrating consistent histologic expression of SSTR1, 2a, 4, and 5 in VHL-HBs. We found that somatostatin analogue octreotide induces apoptosis in VHL-HB stromal cells in a dose-dependent fashion by BAX \u2013 caspase-3 pathway unrelated to canonical VHL pathway. When administered to a patient with unresectable symptomatic suprasellar hemangioblastoma, octreotide resulted in tumor volume reduction, symptom stabilization, and tumor cytopenia on repeat <jats:sup>68<\/jats:sup>Ga-DOTA-TATE positron emission tomography (PET) within 6 months, suggesting tumor infarction. We conclude that VHL-HBs harbor multiple SSTR subtypes that offer actionable chemo-therapeutic strategy for management of symptomatic, unresectable tumors by somatostatin analogue therapy.<\/jats:p>","DOI":"10.1038\/srep40822","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T12:07:54Z","timestamp":1484654874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target"],"prefix":"10.1038","volume":"7","author":[{"given":"Saman","family":"Sizdahkhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Ksendzovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhik","family":"Ray-Chaudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragan","family":"Maric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsha J.","family":"Merrill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengping","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Chittiboina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"BFsrep40822_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/jmg.33.2.120","volume":"33","author":"IR Maddock","year":"1996","unstructured":"Maddock, I. R. et al. A genetic register for von Hippel-Lindau disease. J. Med. Genet. 33, 120\u2013127 (1996).","journal-title":"J. Med. Genet."},{"key":"BFsrep40822_CR2","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317\u20131320 (1993).","journal-title":"Science"},{"key":"BFsrep40822_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/B978-0-444-62702-5.00010-X","volume":"132","author":"P Chittiboina","year":"2015","unstructured":"Chittiboina, P. & Lonser, R. R. Von Hippel-Lindau disease. Handb. Clin. Neurol. 132, 139\u201356 (2015).","journal-title":"Handb. Clin. Neurol."},{"key":"BFsrep40822_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3171\/2014.1.JNS131431","volume":"120","author":"RR Lonser","year":"2014","unstructured":"Lonser, R. R. et al. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J. Neurosurg. 120, 1055\u201362 (2014).","journal-title":"J. Neurosurg."},{"key":"BFsrep40822_CR5","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1586\/ern.11.124","volume":"11","author":"JJ Wind","year":"2011","unstructured":"Wind, J. J. & Lonser, R. R. Management of von Hippel-Lindau disease-associated CNS lesions. Expert Rev. Neurother. 11, 1433\u201341 (2011).","journal-title":"Expert Rev. Neurother"},{"key":"BFsrep40822_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/pbc.22065","volume":"53","author":"I Sardi","year":"2009","unstructured":"Sardi, I. et al. Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease. Pediatr. Blood Cancer 53, 464\u20137 (2009).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFsrep40822_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-010-0244-3","volume":"101","author":"LR Rogers","year":"2011","unstructured":"Rogers, L. R. et al. Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: A case report. J. Neurooncol. 101, 307\u2013310 (2011).","journal-title":"J. Neurooncol."},{"key":"BFsrep40822_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/1752-1947-6-238","volume":"6","author":"AI Omar","year":"2012","unstructured":"Omar, A. I. Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report. J. Med. Case Rep 6, 238 (2012).","journal-title":"J. Med. Case Rep"},{"key":"BFsrep40822_CR9","doi-asserted-by":"crossref","unstructured":"Aiello, L. P., George, D. J. & Cahill, M. T. Rapid and Durable Recovery of Visual Function in a Patient with von Hippel- Lindau Syndrome after Systemic Therapy with Vascular Endothelial Growth Factor Receptor Inhibitor SU5416. 1745\u20131751 (2002).","DOI":"10.1016\/S0161-6420(02)01159-4"},{"key":"BFsrep40822_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.critrevonc.2012.10.001","volume":"86","author":"JF Capitanio","year":"2013","unstructured":"Capitanio, J. F., Mazza, E., Motta, M., Mortini, P. & Reni, M. Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system. Crit. Rev. Oncol. Hematol. 86, 69\u201384 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"BFsrep40822_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","volume":"49","author":"A Wilding","year":"2012","unstructured":"Wilding, A. et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J. Med. Genet. 49, 264\u2013269 (2012).","journal-title":"J. Med. Genet."},{"key":"BFsrep40822_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/path.2435","volume":"216","author":"SB Shively","year":"2008","unstructured":"Shively, S. B. et al. Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease. J. Pathol. 216, 514\u201320 (2008).","journal-title":"J. Pathol."},{"key":"BFsrep40822_CR13","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1371\/journal.pmed.0040060","volume":"4","author":"DM Park","year":"2007","unstructured":"Park, D. M. et al. von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med. 4, e60 (2007).","journal-title":"PLoS Med."},{"key":"BFsrep40822_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0301-472X(01)00772-X","volume":"30","author":"SPMA Oomen","year":"2002","unstructured":"Oomen, S. P. M. A. et al. Somatostatin is a selective chemoattractant for primitive (CD34(+)) hematopoietic progenitor cells. Exp. Hematol. 30, 116\u201325 (2002).","journal-title":"Exp. Hematol"},{"key":"BFsrep40822_CR15","doi-asserted-by":"crossref","unstructured":"De Martino, M. C., Hofland, L. J. & Lamberts, S. W. J. Somatostatin and somatostatin receptors: from basic concepts to clinical applications. Progress in brain research 182, (Elsevier B.V., 2010).","DOI":"10.1016\/S0079-6123(10)82011-4"},{"key":"BFsrep40822_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s13139-012-0133-0","volume":"46","author":"J-R Oh","year":"2012","unstructured":"Oh, J.-R. et al. Ga-68 Somatostatin Receptor PET\/CT in von Hippel-Lindau Disease. Nucl. Med. Mol. Imaging (2010). 46, 129\u201333 (2012).","journal-title":"Nucl. Med. Mol. Imaging (2010)."},{"key":"BFsrep40822_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3348\/kjr.2014.15.1.169","volume":"15","author":"P Sharma","year":"2014","unstructured":"Sharma, P., Dhull, V. S., Bal, C., Malhotra, A. & Kumar, R. Von Hippel-Lindau syndrome: demonstration of entire disease spectrum with (68)Ga-DOTANOC PET-CT. Korean J. Radiol. 15, 169\u201372 (2014).","journal-title":"Korean J. Radiol."},{"key":"BFsrep40822_CR18","doi-asserted-by":"crossref","unstructured":"Cives, M. & Strosberg, J. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. Drugs 847\u2013858, doi: 10.1007\/s40265-015-0397-7 (2015).","DOI":"10.1007\/s40265-015-0397-7"},{"key":"BFsrep40822_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin, M. E. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224\u201333 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep40822_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nrd1255","volume":"2","author":"G Weckbecker","year":"2003","unstructured":"Weckbecker, G. et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov. 2, 999\u20131017 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFsrep40822_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi, J. C. et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27, 273\u2013282 (2000).","journal-title":"Eur. J. Nucl. Med."},{"key":"BFsrep40822_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0039-6060(96)80293-5","volume":"120","author":"WE Fisher","year":"1996","unstructured":"Fisher, W. E. et al. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery 120, 234\u201340\u20131 (1996).","journal-title":"Surgery"},{"key":"BFsrep40822_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.prp.2015.03.003","volume":"211","author":"T Schaller","year":"2015","unstructured":"Schaller, T. et al. Specific immunohistochemical pattern of carbonic anhydrase IX is helpful for the diagnosis of CNS hemangioblastoma. Pathol. Res. Pract. 211, 513\u2013520 (2015).","journal-title":"Pathol. Res. Pract."},{"key":"BFsrep40822_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003088-199325050-00004","volume":"25","author":"P Chanson","year":"1993","unstructured":"Chanson, P., Timsit, J. & Harris, A. G. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin. Pharmacokinet 25, 375\u201391 (1993).","journal-title":"Clin. Pharmacokinet"},{"key":"BFsrep40822_CR25","doi-asserted-by":"publisher","first-page":"25733","DOI":"10.1074\/jbc.M002740200","volume":"275","author":"ME Cockman","year":"2000","unstructured":"Cockman, M. E. et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733\u201341 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFsrep40822_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"BFsrep40822_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0895-822","volume":"1","author":"O Iliopoulos","year":"1995","unstructured":"Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W. G. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1, 822\u20136 (1995).","journal-title":"Nat. Med"},{"key":"BFsrep40822_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/jjco\/29.7.323","volume":"29","author":"K Suzuki","year":"1999","unstructured":"Suzuki, K. et al. Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro . Jpn. J. Clin. Oncol. 29, 323\u2013331 (1999).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"BFsrep40822_CR29","first-page":"1380","volume":"25","author":"H Liu","year":"2004","unstructured":"Liu, H., Huo, L. & Wang, L. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol. Sin. 25, 1380\u20131386 (2004).","journal-title":"Acta Pharmacol. Sin."},{"key":"BFsrep40822_CR30","first-page":"760","volume":"84","author":"K Manoj","year":"2004","unstructured":"Manoj, K., Liu, Z. R., Tian, R. & Qin, R. Y. [Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype 2]. Zhonghua Yi Xue Za Zhi 84, 760\u2013765 (2004).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"BFsrep40822_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","volume":"30","author":"JC Reubi","year":"2003","unstructured":"Reubi, J. C. & Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 30, 781\u2013793 (2003).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFsrep40822_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1530\/EJE-07-0562","volume":"158","author":"GF Taboada","year":"2008","unstructured":"Taboada, G. F. et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur. J. Endocrinol. 158, 295\u2013303 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"BFsrep40822_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","volume":"12","author":"APM Casarini","year":"2009","unstructured":"Casarini, A. P. M. et al. Acromegaly: Correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12, 297\u2013303 (2009).","journal-title":"Pituitary"},{"key":"BFsrep40822_CR34","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1523\/JNEUROSCI.20-10-03785.2000","volume":"20","author":"M Schreff","year":"2000","unstructured":"Schreff, M. et al. Distribution, targeting, and internalization of the sst4 somatostatin receptor in rat brain. J. Neurosci. 20, 3785\u201397 (2000).","journal-title":"J. Neurosci."},{"key":"BFsrep40822_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-0115(00)00108-7","volume":"90","author":"I Selmer","year":"2000","unstructured":"Selmer, I., Schindler, M., Allen, J. P., Humphrey, P. P. & Emson, P. C. Advances in understanding neuronal somatostatin receptors. Regul. Pept. 90, 1\u201318 (2000).","journal-title":"Regul. Pept."},{"key":"BFsrep40822_CR36","doi-asserted-by":"publisher","first-page":"926295","DOI":"10.1155\/2013\/926295","volume":"2013","author":"F Barbieri","year":"2013","unstructured":"Barbieri, F. et al. Peptide receptor targeting in cancer: the somatostatin paradigm. Int. J. Pept. 2013, 926295 (2013).","journal-title":"Int. J. Pept"},{"key":"BFsrep40822_CR37","first-page":"8","volume":"26","author":"LJ Hofland","year":"2003","unstructured":"Hofland, L. J. Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog. J. Endocrinol. Invest. 26, 8\u201313 (2003).","journal-title":"J. Endocrinol. Invest."},{"key":"BFsrep40822_CR38","doi-asserted-by":"publisher","first-page":"E1078","DOI":"10.1152\/ajpendo.00292.2009","volume":"297","author":"F Barbieri","year":"2009","unstructured":"Barbieri, F. et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am. J. Physiol. Endocrinol. Metab. 297, E1078\u201388 (2009).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFsrep40822_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/JOE-16-0332","volume":"231","author":"A Ib\u00e1\u00f1ez-Costa","year":"2016","unstructured":"Ib\u00e1\u00f1ez-Costa, A. et al. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro . J. Endocrinol. 231, 135\u2013145 (2016).","journal-title":"J. Endocrinol."},{"key":"BFsrep40822_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1006\/bbrc.1995.1517","volume":"209","author":"CB Srikant","year":"1995","unstructured":"Srikant, C. B. Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. Biochem. Biophys. Res. Commun. 209, 400\u20136 (1995).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFsrep40822_CR41","doi-asserted-by":"crossref","unstructured":"Teijeiro, R. et al. Cellular Physiology Biochemistry and Biochemistr y Activation of Human Somatostatin Receptor 2 Promotes Apoptosis Through a Mechanism that is Independent from Induction of p53. Identity 31\u201338 (2002).","DOI":"10.1159\/000047824"},{"key":"BFsrep40822_CR42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2967\/jnmt.114.139238","volume":"42","author":"S Basu","year":"2014","unstructured":"Basu, S. & Abhyankar, A. The Use of 99mTc-HYNIC-TOC and 18F-FDG PET\/CT in the Evaluation of Duodenal Neuroendocrine Tumor with Atypical and Extensive Metastasis Responding Dramatically to a Single Fraction of PRRT with 177Lu-DOTATATE. J. Nucl. Med. Technol. 42, 296\u2013298 (2014).","journal-title":"J. Nucl. Med. Technol."},{"key":"BFsrep40822_CR43","first-page":"312","volume":"24","author":"G Vural","year":"1997","unstructured":"Vural, G. et al. Comparison of indium-111 octreotide and thallium-201 scintigraphy in patients mammographically suspected of having breast cancer: Preliminary results. Eur. J. Nucl. Med. 24, 312\u2013315 (1997).","journal-title":"Eur. J. Nucl. Med."},{"key":"BFsrep40822_CR44","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","volume":"17","author":"C Susini","year":"2006","unstructured":"Susini, C. & Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 17, 1733\u201342 (2006).","journal-title":"Ann. Oncol."},{"key":"BFsrep40822_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/er.2000-0001","volume":"24","author":"LJ Hofland","year":"2003","unstructured":"Hofland, L. J. & Lamberts, S. W. J. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 24, 28\u201347 (2003).","journal-title":"Endocr. Rev."},{"key":"BFsrep40822_CR46","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1043-2760(02)00667-7","volume":"13","author":"SWJ Lamberts","year":"2002","unstructured":"Lamberts, S. W. J., de Herder, W. W. & Hofland, L. J. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrin. Met 13, 451\u2013457 (2002).","journal-title":"Trends Endocrin. Met"},{"key":"BFsrep40822_CR47","doi-asserted-by":"crossref","unstructured":"Rinke, A. et al. Placebo Controlled, Double Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results on Long Term Survival. Neuroendocrinology, doi: 10.1159\/000443612 (2016).","DOI":"10.1159\/000443612"},{"key":"BFsrep40822_CR48","unstructured":"FDA approves marketing of octreotide. Clin. Pharm. 8, 4 (1989)."},{"key":"BFsrep40822_CR49","first-page":"212","volume":"11","author":"Y Ligier","year":"1994","unstructured":"Ligier, Y., Ratib, O., Logean, M. & Girard, C. Osiris: a medical image-manipulation system. MD. Comput. 11, 212\u20138 (1994).","journal-title":"MD. Comput"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep40822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40822","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:43:39Z","timestamp":1671842619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep40822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,9]]}},"alternative-id":["BFsrep40822"],"URL":"https:\/\/doi.org\/10.1038\/srep40822","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,17]]},"assertion":[{"value":"23 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40822"}}